课题基金 / 基金详情

Novel Bio-synthetic Matrix For Ocular Surface Reconstruction

Novel Bio-synthetic Matrix For Ocular Surface Reconstruction
用于眼表重建的新型生物合成基质
批准号:
G0601773/1
负责人:
Naing Tint
金额:
$11.63万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2008
资助国家:
英国
项目状态:
已结题
起止时间:
2008 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Lay DescriptionThe cornea can be affected by infection, inflammation or trauma resulting in pain and potential blindness. The amniotic membrane (a membrane that surrounds a baby in the womb) has healing qualities which can be used in surgery to prevent scarring and promote healing of such corneal diseases. However, results can be unpredictable due to bio-chemical variations of the amniotic membrane. Also there is potential risk of cross-infection even though appropriate screening has been undertaken. We propose a collaboration between the Division of Ophthalmology and materials specialist (Tissue Engineering Group), to develop a synthetic material which resembles this membrane but is standardised and readily available. Currently, we are able to grow cells which are beneficial to the wound healing process in vitro. We hope to combine this technology with the expertise of material scientist to generate an artificial matrix that will support the growth of these cells and may be used to aid wound healing of the ocular surface. This material can be of benefit in reconstruction of other tissues of the body.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
NGQDs/BiO2-x/PANI新型复合光催化剂的构筑及其可见光催化还原Cr(VI)的性能与机制研究
  • 批准号:
    2026JJ80226
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    唐新德
  • 依托单位:
骨胶原(Bio-Oss Collagen)联合龈下喷砂+骨皮质切开术治疗 根分叉病变的临床疗效研究
  • 批准号:
    2024JJ9542
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    潘涛华
  • 依托单位:
基于通用型 M13-Bio 噬菌体信号放大的动态 光散射免疫传感检测平台的建立及机制研究
  • 批准号:
    Q24C200014
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    湛胜楠
  • 依托单位:
智能双栅调控InSe Bio-FET可控构筑与原位细胞传感机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
  • 依托单位: